CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price traded down 1.6% during trading on Friday . The company traded as low as $39.77 and last traded at $39.96. 641,669 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 1,890,571 shares. The stock had previously closed at $40.61.
CRSP has been the topic of several research reports. JMP Securities restated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Monday, December 30th. Bank of America reduced their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. HC Wainwright assumed coverage on CRISPR Therapeutics in a research report on Monday. They issued a "buy" rating and a $65.00 price target for the company. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $77.59.
Check Out Our Latest Analysis on CRSP
The company has a market cap of $3.39 billion, a P/E ratio of -14.03 and a beta of 1.67. The stock has a 50-day moving average of $42.99 and a two-hundred day moving average of $46.78.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the firm earned ($1.41) EPS. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.1 EPS for the current fiscal year.
In related news, CEO Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.10% of the company's stock.
A number of large investors have recently made changes to their positions in CRSP. Capital Market Strategies LLC bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $461,000. KBC Group NV increased its position in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after buying an additional 57,696 shares during the period. Capital Advisors Inc. OK raised its stake in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock worth $14,122,000 after buying an additional 22,583 shares in the last quarter. Geode Capital Management LLC boosted its position in CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Finally, State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.